Chimeric antigen receptor dendritic cells suppress melanoma growth in preclinical cancer models
Journal for ImmunoTherapy of Cancer · 2025-12 · 13 (12) · e013040
DOI: 10.1136/jitc-2025-013040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 31.12.2025. Verfasst von Julia Minnee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, NYU Grossman School of Medicine, New York, New York, USA. Hauptthemen laut MEDLINE: Dendritic Cells, Receptors, Chimeric Antigen, Immunotherapy, Adoptive, Melanoma, Experimental. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Foundation for the National Institutes of Health.
Abstract (Originalsprache)
Background
Chimeric antigen receptor (CAR)-T cell therapy has been successful for the treatment of hematological cancers but less effective against solid tumors, a phenomenon that results from the immunosuppressive nature of the tumor microenvironment. As a strategy to improve the treatment of solid tumors, we applied CAR therapy to dendritic cells (DCs) to generate CAR-DCs. The CAR targeted the human epidermal growth factor receptor 2 (HER2) which is overexpressed in breast cancer to defeat the immunosuppressive nature of the tumor microenvironment.
Methods
CAR-DCs were generated by lentiviral vector transduction of SAMHD1 knock-out murine bone marrow-derived DCs. The vectors coexpressed CD40L and a soluble form of programmed cell death 1 (PD-1), a checkpoint inhibitor. To increase the durability of CAR-DCs, a gene encoding the cytokine GM-CSF was introduced into the CAR vector. The CAR-DCs were injected into mice bearing B16.HER2 melanoma tumors. Tumor growth was measured, and T cell functionality was determined by IFNγ expression and in vitro cytolytic assay.
Results
CAR-DCs suppressed the growth of B16.HER2 tumors and induced the proliferation and activation of tumor-infiltrating cytolytic CD8+T cells. The PD-1 checkpoint inhibitor further augmented the antitumor response and prevented T cell exhaustion. Vectored expression of GM-CSF increased the durability of the antitumor response.
Conclusions
CAR-DCs could be an effective strategy for therapies against solid tumors that should be further explored. The approach relies on the antigen-presenting ability of DCs and their role in T cell activation and can be coupled with checkpoint inhibition in place of monoclonal antibody treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, NYU Grossman School of Medicine, New York, New York, USA.
- Department of Microbiology, NYU Grossman School of Medicine, New York, New York, USA nathaniel.landau@med.nyu.edu.
Förderung
- Foundation for the National Institutes of Health
Zitieren
APA
Minnee, J., Wong, W. Z., Russell, B. S., Semana, J. L., Li, R., Landau, N. R., & Tada, T. (2025). Chimeric antigen receptor dendritic cells suppress melanoma growth in preclinical cancer models. Journal for ImmunoTherapy of Cancer, 13(12), e013040. https://doi.org/10.1136/jitc-2025-013040
Vancouver
Minnee J, Wong WZ, Russell BS, Semana JL, Li R, Landau NR, et al. Chimeric antigen receptor dendritic cells suppress melanoma growth in preclinical cancer models. Journal for ImmunoTherapy of Cancer. 2025;13(12):e013040. doi:10.1136/jitc-2025-013040
BibTeX
@article{Minnee2025,
author = {Minnee, Julia and Wong, Wallace Zh and Russell, Benjamin S and Semana, Jose Lm and Li, Ruofan and Landau, Nathaniel R and Tada, Takuya},
title = {Chimeric antigen receptor dendritic cells suppress melanoma growth in preclinical cancer models},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2025},
volume = {13},
number = {12},
pages = {e013040},
doi = {10.1136/jitc-2025-013040}
}
EUVIMED